


Cervix Cancer Research Network

Chair: Mary McCormack

**Steering Committee: Marie Plante, David Gaffney,
Sang Young Ryu, Bill Small, Carien Creutzberg, D.
Thinh, Anuja Jhingran, Linus Chuang, Linda
Mileshkin, Al Covens (IGCS), Jonathan Berek
(FIGO) and Monica Bacon**

Gynecologic Cancer InterGroup Cervix Cancer Research Network



- 4th most common cancer women
- Over 500,000 new cases/260,000 deaths per year
- Mortality varies 2-27/100,000
- Cancer burden likely to rise

FIGURE 11. Cervical Cancer Incidence and Mortality Rates by World Area.

Global Cancer Statistics, 2012. CA Cancer J Clin;65-87-108, 2015




Health, equity, and women's cancers 1




The global burden of women's cancers: a grand challenge in global health

Ophira Ginsburg, Freddie Bray, Michel P Coleman, Verna Vanderpuye, Alexandru Eniu, S Rani Kotha, Malabika Sarker, Tran Thanh Huong, Claudia Allemani, Allison Dvaladze, Julie Gralow, Karen Yeates, Carolyn Taylor, Nandini Oomman, Suneeta Krishnan, Richard Sullivan, Dominista Kombe, Magaly M Blas, Groesbeck Parham, Natasha Kassami, Lesong Conteh


Lancet 2017,389



Cervical Cancer



CCRN background



What is CCRN ?

- A Network of sites with expertise in the management of cervical cancer
- Established in 2011 by Prof Henry Kitchener & managed by GCIG
- These sites are generally in LMIC
- Common goal to promote research and good clinical practice in the treatment of women with cervical cancer
- Recognised that participation in research raises the standards for all patients.
- Inclusion of patients from diverse ethical and cultural backgrounds in clinical trials is essential to validate potentially practice changing approaches.

Current CCRN studies

EARLY
STAGE
DISEASE

SHAPE (NCIC)

SENTICOL
III(GINECO)


LOCALLY
ADVANCED

INTERLACE
(NCRI)

TACO (KGOG)

Hypofrac (G-
GOC)

CCRN standard operating procedure



Prequalifying questionnaire


- Site information-contacts/ number of cancers/Gyn ca/Cervix
- Site resources-pathology/radiology/ IT/ indemnity insurance
- Clinical trials ops-CTU/Personnel /tumour boards/ previous trials experience/details of ethics and regulatory approval processes
- Radiation therapy –facilities/documentation/dosimetry audit/treatment verification/patient pathway

Capability questionnaire

- 1. Are your clinical trial subjects entitled to medical management without cost as long as required; and entitled to financial compensation for clinical trial related injury or death?**
- 2. Do you have (national) definitions of what constitutes 'clinical trial related injury or death'?**
- 3. Do you follow ICH Good Clinical Practice [GCP] Guidelines?**
- 4. As well as protocol-mandated reporting through the data reporting mechanism, is there a national regulatory procedure for reporting serious adverse events .**

Current CCRN sites

Fig. 1. Worldwide incidences of cervical cancer per 100 000 females (all ages), age-standardized to the WHO standard population, 2005⁴



Blue-activated
 Red -approved
 Gold- not approved


Meeting objectives

- Establish new partnerships to further care of women with cervical cancer
- Facilitate the exchange of ideas in developing new trials
- Highlight ongoing CCRN trials
- Refresh our knowledge on current best practice


International clinical trials- Challenges



GCI:G: Then and Now



GCIG: 27 Groups



7 groups in North America

14 groups in Europe

6 groups in Asia/Australia